Zafgen is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by complex metabolic diseases, including type 2 diabetes and obesity.

Zafgen is leveraging its experience with the MetAP2 pathway to develop therapeutics that address the underlying biological mechanisms of metabolic disease. The Company’s lead product candidate is ZGN-1061, which is a novel, first-in-class, twice-weekly subcutaneous injection. Zafgen is well-capitalized and has assembled a team accomplished in bringing therapies to patients affected by metabolic disease.